Roquette Frères

Is Roquette publicly traded?
No. Roquette Frères is a private, family-owned company with no stock exchange listing. The Roquette family holds the share capital through a holding structure and has controlled the business across five generations since 1933. Financial results are disclosed voluntarily through annual reports and press releases rather than regulatory filings.

Who owns Roquette?
Roquette is owned by members of the Roquette family, descendants of founders Dominique and Germain Roquette. The family controls the board while professional managers run daily operations. Thierry Fournier has served as chief executive, leading the group through the 2025 acquisition of IFF Pharma Solutions.

When was Roquette founded?
Roquette was founded in 1933 by brothers Dominique and Germain Roquette in Lestrem, northern France, originally as a potato starch producer serving local farmers. It expanded into wheat and corn processing after World War II and into pharmaceutical ingredients and plant proteins from the 2000s onward.

What does Roquette make?
Roquette converts plant crops into starches, sweeteners, polyols, fibers, and proteins for food manufacturers, and excipients and specialty ingredients for pharmaceutical companies. Its best-known product lines are NUTRALYS pea protein for food applications and, after the 2025 IFF acquisition, Avicel and METHOCEL excipients for drug tablets.

How big is Roquette?
In 2025 Roquette reported turnover of EUR 4,877 million and current EBITDA of EUR 612 million. It employs more than 11,000 people at over 40 manufacturing sites and 20 R&D centers, selling to customers in more than 150 countries. It is one of the largest family-owned ingredient companies in the world.

What did Roquette buy in 2025?
On May 1, 2025, Roquette completed the acquisition of IFF Pharma Solutions for a reported approximately $2.85 billion, the largest deal in its history. The business adds excipients including Avicel microcrystalline cellulose and METHOCEL, making Roquette the global leader in oral solid dosage form excipients and expanding its Health & Pharma Solutions unit to 27 percent of sales.

Brothers Dominique and Germain Roquette founded the company in 1933 in Lestrem, a farming town in the Nord department of northern France, building a potato starch plant to serve local agriculture. The region's abundant potato and cereal crops provided the raw material base, and starch extraction for food and industrial uses formed the original business.

Through the postwar decades Roquette expanded from potato starch into wheat and corn processing, sweeteners, and sugar alcohols. It commissioned large grain processing plants at Lestrem and added polyols such as sorbitol and maltitol, which became staples of the sugar-free confectionery and oral care industries. By the 1990s the company had established manufacturing in Italy, Spain, the United States, and China.

The 2000s brought a deliberate move upmarket. Roquette invested in plant protein research and launched NUTRALYS pea protein, riding early demand for plant-based food ingredients. It built one of the world's largest pea protein plants in Portage la Prairie, Manitoba, which opened in 2021, and developed pharmaceutical-grade excipients for tablet formulation and drug delivery.

The Roquette family maintained control throughout, with leadership passing through successive generations before the appointment of outsider Pierre Courduroux and later Thierry Fournier as chief executive while the family retained the board majority.

The defining recent event was the acquisition of IFF's Pharma Solutions business, completed on May 1, 2025 for a reported approximately $2.85 billion. The deal added the iconic Avicel microcrystalline cellulose brand, METHOCEL, and excipient plants in the United States, France, and elsewhere. Roquette's 2025 turnover rose 8 percent to EUR 4,877 million, with Health & Pharma Solutions sales nearly doubling, while current EBITDA rose 13 percent to EUR 612 million. A second pea protein facility and expanded excipient capacity were announced as part of a multi-year investment program.

Roquette positions itself as a plant-based sustainability business and publishes annual reporting on sourcing, emissions, and product footprint. It operates supplier programs for regenerative agriculture practices among the farmers supplying its European plants and has publicized investments in biomass energy and water treatment at its largest sites.

The company's business model is structurally tied to agricultural sustainability claims: pea protein marketing leans on the crop's low nitrogen requirement, and bioindustry products are sold as substitutes for petrochemical inputs. Critics note that such claims are largely self-assessed, and Roquette does not carry B Corp certification.

On social responsibility, the company emphasizes local sourcing relationships in the Hauts-de-France region, where it is a major employer, and runs apprenticeship and agricultural training programs with member suppliers.

Roquette has maintained a relatively low public controversy profile. The most consequential recent scrutiny is financial rather than ethical: the debt load taken on for the IFF Pharma Solutions acquisition increased leverage to 3.48 times EBITDA, and credit analysts have watched execution risk on the integration.

Like other French industrial companies, it has faced periodic environmental compliance attention from regional authorities around its Lestrem complex, historically one of Europe's largest starch processing sites, though no major unresolved violations are on record. In 2025 the group reported a net loss of EUR 265 million, driven by EUR 335 million in non-recurring items including acquisition costs and a one-off deferred tax charge in the United States, a result it disclosed transparently in its annual report.